These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16831173)

  • 1. Side-effects of treatments for locally advanced prostate cancer.
    Gardiner RF; Nicol DL; Green HJ; Pakenham KI
    BJU Int; 2006 Jul; 98(1):229-30. PubMed ID: 16831173
    [No Abstract]   [Full Text] [Related]  

  • 2. Side-effects of treatments for locally advanced prostate cancer.
    O'Connor KM; Fitzpatrick JM
    BJU Int; 2006 Jan; 97(1):22-8. PubMed ID: 16336322
    [No Abstract]   [Full Text] [Related]  

  • 3. Characteristics and management of erectile dysfunction after various treatments for prostate cancer.
    Soh J; Kaiho Y; Kikuchi E; Oya M; Yoshioka K; Nakagami Y; Hatano T; Ozu C; Horiguchi Y; Namiki K; Tachibana M; Hisasue S; Tanaka N; Asakawa I
    Int J Urol; 2010 Aug; 17(8):689-97. PubMed ID: 20590940
    [No Abstract]   [Full Text] [Related]  

  • 4. Androgen suppression therapy and prostate cancer: balancing the harms and the benefits.
    Oefelein MG
    Cancer; 2008 Dec; 113(12):3275-8. PubMed ID: 18988289
    [No Abstract]   [Full Text] [Related]  

  • 5. Side-effects of treatments for locally advanced prostate cancer.
    Reid Pitts W
    BJU Int; 2006 Jun; 97(6):1347. PubMed ID: 16686737
    [No Abstract]   [Full Text] [Related]  

  • 6. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
    Polascik TJ
    Prostate Cancer Prostatic Dis; 2008; 11(1):13-9. PubMed ID: 17923854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.
    Bolla M; Descotes JL; Artignan X; Fourneret P
    BJU Int; 2007 Jul; 100 Suppl 2():44-7. PubMed ID: 17594359
    [No Abstract]   [Full Text] [Related]  

  • 8. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
    Kaprin AD; Kostin AA; Tsybul'skiĭ AD
    Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiandrogens in the treatment of prostate cancer.
    Wirth MP; Hakenberg OW; Froehner M
    Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 16. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.
    D'Amico AV; Denham JW; Bolla M; Collette L; Lamb DS; Tai KH; Steigler A; Chen MH
    Cancer; 2007 May; 109(10):2004-10. PubMed ID: 17397033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 19. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.
    Castro Mendez L; Martell K; Crook JM
    J Clin Oncol; 2020 Nov; 38(32):3820-3821. PubMed ID: 32997576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.